Switching to, then stopping treatment with nilotinib for CML patients.

  • Research type

    Research Study

  • Full title

    A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.

  • IRAS ID

    146148

  • Contact name

    Jane Apperley

  • Contact email

    j.apperley@imperial.ac.uk

  • Sponsor organisation

    Novartis Pharma Services AG

  • Eudract number

    2012-005124-15

  • REC name

    London - Hampstead Research Ethics Committee

  • REC reference

    14/LO/0521

  • Date of REC Opinion

    23 May 2014

  • REC opinion

    Further Information Favourable Opinion